期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 76, 期 3, 页码 467-474出版社
WILEY
DOI: 10.1111/bcp.12159
关键词
clinical trial; CYP3A4; docetaxel; Echinacea purpurea; herb-drug interactions; pharmacokinetics
资金
- Dutch Cancer Society [UU 2007-3795]
AimsThe herbal medicine Echinacea purpurea (E. purpurea) has been shown to induce cytochrome P450 3A4 (CYP3A4) both in vitro and in humans. This study explored whether E. purpurea affects the pharmacokinetics of the CYP3A4 substrate docetaxel in cancer patients. MethodsTen evaluable cancer patients received docetaxel (135mg, 60min IV infusion) before intake of a commercially available E. purpurea extract (20 oral drops three times daily) and 3 weeks later after a 14 day supplementation period with E. purpurea. In both cycles, pharmacokinetic parameters of docetaxel were determined. ResultsBefore and after supplementation with E. purpurea, the mean area under the plasma concentration-time curve of docetaxel was 3278 1086 and 3480 +/- 1285ngml(-1)h, respectively. This result was statistically not significant. Nonsignificant alterations were also observed for the elimination half-life (from 30.8 +/- 19.7 to 25.6 +/- 5.9h, P = 0.56) and maximum plasma concentration of docetaxel (from 2224 +/- 609 to 2097 +/- 925ngml(-1), P = 0.30). ConclusionsThe multiple treatment of E. purpurea did not significantly alter the pharmacokinetics of docetaxel in this study. The applied E. purpurea product at the recommended dose may be combined safely with docetaxel in cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据